Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Portal hypertension is a lethal complication of cirrhosis. Its mechanism and therapeutic targets remain largely unknown. Hepatic stellate cell (HSC) contraction increases intrahepatic vascular resistance contributing to portal hypertension. We investigated how HSC contraction was regulated by Wnt signaling and the therapeutic implication.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Liver tissues from cirrhotic patients were examined. Cirrhotic mice with genetic or pharmacological treatments were used for <i>in vivo</i> assessments and their primary cells were isolated. Cellular functions and signaling pathways were analyzed in human HSC‐LX2 cells using real‐time PCR, Western blotting, siRNA, luciferase reporter assay, chromatin immunoprecipitation, co‐immunoprecipitation, and site‐directed mutagenesis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Wnt/β‐catenin correlated with HSC contraction in human cirrhotic liver. Wnt3a stimulated Smo‐independent Gli1 nuclear translocation followed by LARG‐mediated RhoA activation leading to HSC contraction. Sufu negatively mediated Wnt3a‐induced Gli1 nuclear translocation. Wnt/β‐catenin repressed the transcription of Sufu dependent on β‐catenin/TCF4 interaction and TCF4 binding to Sufu promoter. Molecular simulation and site‐directed mutagenesis identified the β‐catenin residues Lys312 and Lys435 critically involved in the interaction. Additionally, TCF4 binding to the sequence CACACCTTCC at Sufu promoter was required for transrepression of Sufu. In cirrhotic mice, short‐term liver‐targeting β‐catenin deficiency or acute treatment with β‐catenin inhibitors reduced portal pressure via restriction of HSC contraction rather than inhibition of HSC activation. Long‐term deficiency or treatments also ameliorated liver injury, fibrosis and inflammation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions and Implications</h3><p>Interaction between Wnt/β‐catenin and Smo‐independent Gli1 pathways promoted HSC contraction via TCF4‐dependent transrepression of Sufu. HSC‐specific inhibition of β‐catenin may have therapeutic benefits for cirrhotic portal hypertension.</p></section>

Experimental study of activation of mtor/p70s6k signaling pathway in liver cirrhotic portal hypertension

Therapeutic Effect of Mtor Inhibitor Rapamycin in Early Phase Cirrhotic Portal Hypertension of Rats

Experimental study on activation of mTOR signaling pathway promoting mesenteric angiogenesis in portal hyper-tensive rats

Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats Through Inhibition of Mtorc1 but Not Mtorc2.

Association between PI3K/Akt/mTOR/p70S6K signaling pathway and hepatic fibrosis

The in Vitro Effects of Phospholipase D1-mTOR Axis in Liver Fibrogenesis.

The Effect on Liver Fibrosis and Portal Pressure after Administration of Expression Vector Encoding for Endothelial Growth Factor D in Biliary Cirrhotic Rats

Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β‐catenin signalling via interaction with Gli1

Transcriptome Analysis of Mesenteric Arterioles Changes and Its Mechanisms in Cirrhotic Rats with Portal Hypertension.

Research progress on signaling pathways in cirrhotic portal hypertension

Histopathological and hemodynamic changes of rats with liver cirrhosis

Changes of hemodynamics and portal vein pressure in the progression of portal hypertension in rats

Expression of TGFβ1 and its receptors,Smad3 andSmad7 in rats with experi-mental liver fibrosis

Differential Expression Genes Analyzed by Cdna Array in the Regulation of Rat Hepatic Fibrogenesis

Intrahepatic upregulation of MRTF-A signaling contributes to increased hepatic vascular resistance in cirrhotic rats with portal hypertension.

The gene expression anti role of Wnt signal pathway in liver fibrosis

The Response of Rat's Hepatic Fibrosis to TGF-β Signalling

Activation of the Mir-34A/sirt1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis Via Inducing Apoptosis in Hepatocytes but Not in HSCs.

Microrna-377 Is Associated With Portal Hypertension In Rat Liver Cirrhosis By Repressing Heme Oxygenase-1

Mtor Activation Protects Liver from Ischemia/reperfusion‐induced Injury Through NF‐κB Pathway

Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats